⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CORT News
Corcept Therapeutics Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
accessnewswire.com
CORT
Raggiunto l'endpoint primario della sopravvivenza globale nel trial pivotale di fase 3 ROSELLA con Relacorilant in pazienti con carcinoma ovarico resistente al platino di Corcept
businesswire.com
CORT
Primair eindpunt van algehele overleving voldaan in Corcepts cruciale Fase 3-studie ROSELLA van relacorilant bij patiënten met platina-resistente eierstokkanker
businesswire.com
CORT
Critère principal de survie globale atteint dans l’essai pivot ROSELLA de phase 3 de Corcept évaluant le rélacorilant chez les patientes atteintes d’un cancer de l’ovaire résistant au platine
businesswire.com
CORT
El crucial ensayo ROSELLA fase 3 de relacorilant de Corcept cumplió el criterio de evaluación principal de supervivencia general en pacientes con cáncer ovárico resistente al platino
businesswire.com
CORT
Primärer Endpunkt der Gesamtüberlebensrate in der zulassungsrelevanten Phase-3-Studie ROSELLA von Corcept mit Relacorilant bei Patientinnen mit platinresistentem Eierstockkrebs erreicht
businesswire.com
CORT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
prnewswire.com
CORT
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
businesswire.com
CORT
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
prnewswire.com
CORT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
accessnewswire.com
CORT